Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00611104 · ClinicalTrials.gov registry record

Studying the Effect of Freeze-Dried Table Grape Powder on Blood Estrogen Levels in Postmenopausal Women

A clinical trial, sponsored by Mayo Clinic.

Completed
Registry status
20
Enrollment target

NCT00611104: Completed study, sponsored by Mayo Clinic.

NCT00611104 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00611104 has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
20 participants
Enrollment target

Study Summary

RATIONALE: Estrogen can cause the growth of breast cancer cells. Studying samples of blood and urine in the laboratory from participants receiving freeze-dried table grape powder may help doctors understand the effect of this drug on blood estrogen levels. PURPOSE: This clinical trial is studying the effect of freeze-dried table grape powder on blood estrogen levels in postmenopausal women.

Interventions

  • OTHER laboratory biomarker analysis
  • OTHER pharmacological study
  • DIETARY_SUPPLEMENT standardized freeze-dried table grape powder

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2008-08-04
Est. Completion 2014-08-22
Mayo Clinic

2,844 total trials

What the finished NCT00611104 record still lists

NCT00611104 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.

The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.

NCT00611104 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00611104 about?

NCT00611104 is a clinical study titled "Studying the Effect of Freeze-Dried Table Grape Powder on Blood Estrogen Levels in Postmenopausal Women". RATIONALE: Estrogen can cause the growth of breast cancer cells. Studying samples of blood and urine in the laboratory from participants receiving freeze-dried table grape powder may help doctors understand the effect of this drug on blood estrogen levels. PURPOSE: This clinical trial is studying t...

What is the current status of trial NCT00611104?

This trial is currently completed. The enrollment target is 20 participants. The study started on 2008-08-04. Estimated completion is 2014-08-22.

What interventions are being tested in trial NCT00611104?

The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), standardized freeze-dried table grape powder (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT00611104?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00611104, the US trial registry maintained by the National Library of Medicine. NCT00611104 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.